Joann D. Kuruc

TL;DR: It is demonstrated that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

TL;DR: Although HIV latency is disrupted by an initial VOR dose, the effect of subsequent doses in this protocol was much reduced, and it is hypothesized that the global effect of VOR results in a refractory period of ≥ 24 hours.

TL;DR: These findings outline parameters for the experimental use of VOR to clear latent infection and suggest improvements in latency reversal may include the sustained induction of potent antiviral immune responses capable of recognizing and clearing the rare cells in which HIV latency has been reversed.

TL;DR: In this article, a Dual-Affinity Re-Targeting (DART) proteins are employed to improve T cell-mediated clearance of HIV-1-infected cells.

TL;DR: In resource-rich settings, a substantial proportion of residual perinatal transmission may be from HIV acquisition during pregnancy, so algorithms that include pooled HIV RNA testing may improve its detection and represent a further opportunity to prevent perInatal transmission.